- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
Patent holdings for IPC class A61K 31/439
Total number of patents in this class: 2181
10-year publication summary
254
|
203
|
180
|
191
|
201
|
205
|
177
|
183
|
154
|
31
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Wockhardt Limited | 239 |
50 |
Novartis AG | 11238 |
40 |
Genzyme Corporation | 1205 |
35 |
AstraZeneca AB | 3042 |
31 |
Chiesi Farmaceutici S.p.A. | 940 |
31 |
Bristol-myers Squibb Company | 5080 |
26 |
Boehringer Ingelheim International GmbH | 4629 |
26 |
Lenz Therapeutics Operations, Inc. | 31 |
26 |
Merck Sharp & Dohme LLC | 3689 |
24 |
Meiji Seika Pharma Co., Ltd. | 244 |
23 |
Theravance Biopharma R&D IP, LLC | 550 |
20 |
Astellas Pharma Inc. | 1145 |
19 |
Glaxo Group Limited | 4496 |
16 |
Centre National de La Recherche Scientifique | 9632 |
16 |
Vertex Pharmaceuticals Incorporated | 1581 |
16 |
The Scripps Research Institute | 1364 |
15 |
Pfizer Inc. | 3322 |
13 |
Heron Therapeutics, Inc. | 156 |
13 |
Aprea Therapeutics AB | 16 |
13 |
Mutabilis | 27 |
12 |
Other owners | 1716 |